mSphere (Aug 2021)
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma
- Vítor Borges,
- Joana Isidro,
- Mário Cunha,
- Daniela Cochicho,
- Luís Martins,
- Luís Banha,
- Margarida Figueiredo,
- Leonor Rebelo,
- Maria Céu Trindade,
- Sílvia Duarte,
- Luís Vieira,
- Maria João Alves,
- Inês Costa,
- Raquel Guiomar,
- Madalena Santos,
- Rita Cortê-Real,
- André Dias,
- Diana Póvoas,
- João Cabo,
- Carlos Figueiredo,
- Maria José Manata,
- Fernando Maltez,
- Maria Gomes da Silva,
- João Paulo Gomes
Affiliations
- Vítor Borges
- ORCiD
- Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- Joana Isidro
- ORCiD
- Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- Mário Cunha
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Daniela Cochicho
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Luís Martins
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Luís Banha
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Margarida Figueiredo
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Leonor Rebelo
- Clinical Pathology–Virology Lab, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
- Maria Céu Trindade
- Serviço de Hematologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
- Sílvia Duarte
- Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- Luís Vieira
- Innovation and Technology Unit, Department of Human Genetics, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- Maria João Alves
- Centre for Vectors and Infectious Diseases Research, Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- Inês Costa
- National Reference Laboratory for Influenza and other Respiratory Viruses, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
- Raquel Guiomar
- National Reference Laboratory for Influenza and other Respiratory Viruses, Department of Infectious Diseases, National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal
- Madalena Santos
- Laboratório de Biologia Molecular, Serviço de Patologia Clínica do CHULC, Lisbon, Portugal
- Rita Cortê-Real
- Laboratório de Biologia Molecular, Serviço de Patologia Clínica do CHULC, Lisbon, Portugal
- André Dias
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- Diana Póvoas
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- João Cabo
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- Carlos Figueiredo
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- Maria José Manata
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- Fernando Maltez
- Serviço de Doenças Infecciosas do Hospital de Curry Cabral-CHULC, Lisbon, Portugal
- Maria Gomes da Silva
- Serviço de Hematologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
- João Paulo Gomes
- ORCiD
- Bioinformatics Unit, Department of Infectious Diseases, National Institute of Health Dr. Ricardo Jorge (INSA), Lisbon, Portugal
- DOI
- https://doi.org/10.1128/msphere.00244-21
- Journal volume & issue
-
Vol. 6,
no. 4
Abstract
Tracking the within-patient evolution of SARS-CoV-2 is key to understanding how this pandemic virus shapes its genome toward immune evasion and survival. In the present study, by monitoring a long-term COVID-19 immunocompromised patient, we observed the concurrent emergence of mutations potentially associated with immune evasion and/or enhanced transmission, mostly targeting the SARS-CoV-2 key host-interacting protein and antigen.
